Real-World Treatment Patterns and Outcomes of Patients With Acute Myeloid Leukemia in Japan in the Pre-venetoclax Era [0.03%]
维奈克拉时代之前日本急性髓系白血病患者的治疗模式和结局
Shuhei Kida,Shigeo Fuji,Toshitaka Morishima et al.
Shuhei Kida et al.
Background: Acute myeloid leukemia (AML) mainly affects elderly patients, and real-world outcomes are often inferior to those observed in clinical trials. More clinically detailed real-world data are needed to better unde...
Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era [0.03%]
FLT3抑制剂时代异基因造血干细胞移植治疗FLT3内部串联重复突变急性髓系白血病预后变化趋势分析
Atsushi Jinguji,Shuhei Kurosawa,Takashi Toya et al.
Atsushi Jinguji et al.
Background: FLT3 mutations in acute myeloid leukemia (AML) are associated with high relapse rates even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). ...
SOHO State of the Art Updates and Next Questions: Is Favorable-risk AML Always Favorable? [0.03%]
SOHO最新观测及下一步问题：有利风险的AML是否总是有利？
Aditya Tedjaseputra,Nigel Russell,Richard Dillon
Aditya Tedjaseputra
The 2022 European LeukaemiaNet acute myeloid leukemia (AML) classification allocates AML with t(8;21) RUNX1::RUNX1T1 fusion and AML with inv(16) or t(16;16) CBFB::MYH11 fusion (collectively, core-binding factor AML), AML with NPM1 without F...
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection [0.03%]
首次复发多发性骨髓瘤治疗选择专家见解：审慎决策
Samer Al Hadidi,Caitlin Costello,Luciano J Costa et al.
Samer Al Hadidi et al.
Although treatments have greatly improved outcomes in patients with newly diagnosed multiple myeloma (MM), most patients will relapse after initial therapy and require subsequent treatment. With the wide variety of available treatment regim...
Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs [0.03%]
复发性慢性淋巴细胞白血病的治疗进展及新型药物展望
Evani Jain,Chiranjeevi Sainatham,Prithvi Raghavan et al.
Evani Jain et al.
Chronic lymphocytic leukemia (CLL), characterized by the accumulation of mature B lymphocytes in the blood, bone marrow and lymphoid tissues, is the most common adult leukemia in Western countries. The treatment landscape for CLL has evolve...
Autologous Hematopoietic Cell Transplantation (AHCT) for the Treatment of Newly Diagnosed Multiple Myeloma [0.03%]
自体造血细胞移植治疗新诊断的多发性骨髓瘤
Zhubin Gahvari,Natalie S Callander
Zhubin Gahvari
For the past 25 years, autologous hematopoietic cell transplantation (AHCT) has been the cornerstone of therapy for newly diagnosed fit patients with multiple myeloma. However, improved drug therapy, which allows for high rates of remission...
Prophylactic Immunoglobulin Supplementation for Infection Prevention in Multiple Myeloma: An Updated Systematic Review and Meta-Analysis [0.03%]
预防多发性骨髓瘤感染的免疫球蛋白补充治疗：系统评价和 meta 分析的更新版本
Akihiro Miyashita,Shunsuke Kondo,Kensuke Takaoka et al.
Akihiro Miyashita et al.
Background: Patients with multiple myeloma (MM) often have an increased risk of infection. Prophylactic immunoglobulin (Ig) supplementation has been considered a potential strategy to reduce the risk of infections, but it...
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma [0.03%]
嵌合抗原受体T细胞、双特异性抗体和抗体药物偶联物治疗多发性骨髓瘤的研究进展
Lorenzo Cani,Richa Parikh,Nisha S Joseph et al.
Lorenzo Cani et al.
Modern immunotherapies are reshaping the treatment landscape of multiple myeloma (MM), offering the possibility of deeper responses and prolonged survival. Over the past 5 years, chimeric antigen receptor (CAR) T-cell therapies, bispecific ...
Impact of Systemic Inflammatory and Autoimmune Diseases on Outcomes in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia [0.03%]
系统性炎症和自身免疫性疾病对骨髓增生异常综合征和慢性粒单细胞白血病患者结局的影响
Selin Cebeci,Emir Serraç,Tuğrul Elverdi et al.
Selin Cebeci et al.
Objective: Systemic inflammatory and autoimmune diseases (SIADs) are frequently reported in association with myeloid neoplasms; however, their prognostic relevance in myelodysplastic syndromes (MDS) and chronic myelomonoc...
Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance [0.03%]
达拉莫唑单抗为基础的二线疗法改善了VRD诱导治疗、自体移植及来那度胺维持治疗后的疗效
Oren Pasvolsky,Curtis Marcoux,Denái R Milton et al.
Oren Pasvolsky et al.
Background: For eligible patients with newly diagnosed multiple myeloma (MM), induction with VRD used to be the standard of care, followed by autologous stem cell transplantation (autoHCT) and lenalidomide maintenance. Mo...